Company profile
GSK plc
NYSE:GSKBiotechnology: Pharmaceutical Preparations
Drug pipeline (226)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Acetaminophen | approved | — | 78 | approved |
| ACYCLOVIR SODIUM | approved | — | 1 | approved |
| ALBIGLUTIDE | approved | — | 26 | approved |
| Albuterol | approved | — | 47 | approved |
| Albuterol Sulfate | approved | — | 3 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3478)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00056407 | phase3 | completed | 2003-03-01 | 2009-01-01 | GlaxoSmithKline | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk |
| NCT01362348 | phase2 | terminated | 2011-07-07 | 2012-04-16 | GlaxoSmithKline | 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD) |
| NCT00373542 | phase4 | completed | 2006-10-01 | 2007-06-01 | GlaxoSmithKline | 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome |
| NCT00495729 | phase1 | completed | 2007-04-18 | 2007-08-04 | GlaxoSmithKline | 15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects. |
| NCT00318656 | phase4 | completed | 2005-11-01 | 2007-10-01 | GlaxoSmithKline | 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes |
FDA applications (198)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 060060 | ANDA | GLAXOSMITHKLINE | ||||
Loading… | ||||||
| ANDA 060254 | ANDA | GLAXOSMITHKLINE | ||||
Loading… | ||||||
| ANDA 060666 | ANDA | GLAXOSMITHKLINE | ||||
Loading… | ||||||
| ANDA 060677 | ANDA | GLAXOSMITHKLINE | ||||
Loading… | ||||||
| ANDA 061334 | ANDA | GLAXOSMITHKLINE | ||||
Loading… | ||||||